USA flag logo/image

An Official Website of the United States Government

Drug Delivery System for Superficial Mycoses

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
55769
Program Year/Program:
2001 / STTR
Agency Tracking Number:
2R42AI041777-02
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
BIOMEDICAL DEVELOPMENT CORPORATION
A152 ASTeCC Building Lexington, KY 40506-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2001
Title: Drug Delivery System for Superficial Mycoses
Agency: HHS
Contract: PHS2001-2
Award Amount: $365,363.00
 

Abstract:

DESCRIPTION (Provided by the applicant): The goal of this project is to establish the safety and efficacy of a unique drug delivery system for use as a sustained-release, antifungal skin preparation for the treatment of superficial mycoses. The lifetime risk of acquiring a superficial mycotic infection is estimated to be between 10 and 20 percent. In the U.S., annual treatment costs for superficial mycoses exceed $400 million. Immunocompromised and elderly patients are particularly at risk for opportunistic dermatophyte infection, although superficial mycoses often affect people who are otherwise healthy. With an aging population, the increased use of aggressive immunosuppressive therapies, an increase in organ transplants, and the continued prevalence of the AIDS pandemic, the number of patients affected by superficial fungal infection is expected to rise. Phase I studies demonstrated the feasibility of using novel coating compositions for the treatment of superficial mycoses. The Phase II project is designed to further establish the safety and efficacy of the technology. The Specific Aims are to determine the final coating composition based on optimization and evaluation of antifungal delivery, to demonstrate safety of coatings in human studies according to FDA guidelines, and to illustrate the efficacy of coatings in a skin-stripping model in humans. PROPOSED COMMERCIAL APPLICATION: Not Available

Principal Investigator:

H. R. Rawls
2103080636
BDC@BIODEVCORP.COM

Business Contact:

Siegel, gregg
2103080636
GSIEGEL@BIODEVCORP.COM
Small Business Information at Submission:

BIOMEDICAL DEVELOPMENT CORP
500 SANDAU, STE 200 SAN ANTONIO, TX 78216 SAN ANTONIO, TX 78216

EIN/Tax ID: 742330067
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER
SAN ANTONIO, TX 77157
RI Type: Nonprofit college or university